Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.

[1]  N. Girard,et al.  Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Mahadevia,et al.  Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review , 2021, PloS one.

[3]  M. Ladanyi,et al.  Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions , 2021, Clinical Cancer Research.

[4]  N. Girard,et al.  MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations , 2021 .

[5]  P. Parren,et al.  Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET , 2021, The Journal of biological chemistry.

[6]  S. Suissa.  Single-arm Trials with Historical Controls , 2020, Epidemiology.

[7]  A. Cardona,et al.  EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. , 2020, Cancer Treatment Reviews.

[8]  E. Cho,et al.  1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC , 2020 .

[9]  K. Packman,et al.  Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis , 2020, Molecular Cancer Therapeutics.

[10]  J. Neal,et al.  Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. , 2020 .

[11]  S. Heo,et al.  Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. , 2020, Cancer discovery.

[12]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[13]  J. Shih,et al.  Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. , 2019, Clinical lung cancer.

[14]  D. Heo,et al.  Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19) , 2019, Annals of Oncology.

[15]  R. Govindan,et al.  JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). , 2019, Journal of Clinical Oncology.

[16]  Qinghua Zhou,et al.  Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing , 2019, Front. Pharmacol..

[17]  A. Galaznik,et al.  HSR19-084: Real-World Treatment Patterns and Clinical Outcomes in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations , 2019, Journal of the National Comprehensive Cancer Network.

[18]  Paul H. Huang,et al.  Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer , 2019, Signal Transduction and Targeted Therapy.

[19]  A. Forsythe,et al.  HSR19-082: Epidemiological Findings and Outcomes in Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations: A Meta-Analysis , 2019, Journal of the National Comprehensive Cancer Network.

[20]  K. Prabhash,et al.  Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis , 2019, Lung Cancer.

[21]  J. McPherson,et al.  Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  T. Morimoto,et al.  Clinical Characteristics and Prognosis of Patients With Advanced Non–Small‐cell Lung Cancer Who Are Ineligible for Clinical Trials , 2018, Clinical lung cancer.

[23]  Kwok-Kin Wong,et al.  Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer , 2018, Nature Medicine.

[24]  C. Morgan.  Reducing bias using propensity score matching , 2018, Journal of Nuclear Cardiology.

[25]  Chih-Yang Huang,et al.  A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer , 2017, BioMedicine.

[26]  M. Chiu,et al.  Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells , 2016, mAbs.

[27]  P. Parren,et al.  A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. , 2016, Cancer research.

[28]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[29]  T. Betsuyaku,et al.  In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer , 2015, Oncotarget.

[30]  E. Stuart,et al.  Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.

[31]  Geoffrey R. Oxnard,et al.  Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer , 2013, Science Translational Medicine.

[32]  N. Weiss,et al.  Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. , 2013, Journal of the National Cancer Institute.

[33]  V. Gebski,et al.  Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. , 2013, Journal of the National Cancer Institute.

[34]  Suzanne E Dahlberg,et al.  Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  Søren Højsgaard,et al.  The R Package geepack for Generalized Estimating Equations , 2005 .

[36]  V. Cottin,et al.  Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.